Evaluation of the Antimycotic activity of Terconazole proniosomal Gel | ||||
| Egyptian Journal of Medical Microbiology | ||||
| Article 19, Volume 31, Issue 2, April 2022, Page 121-126 PDF (434.75 K) | ||||
| Document Type: New and original researches in the field of Microbiology. | ||||
| DOI: 10.21608/ejmm.2022.229668 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Rehab Bahy  1; Doaa Ahmed Helal2
| ||||
| 1Microbiology and Immunology Faculty of Pharmacy Fayoum university- Fayoum-Egypt | ||||
| 2Department of pharmaceutics, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt. | ||||
| Abstract | ||||
| Background: Terconazole (TCZ) counted is an antifungal drug with a broad spectrum of activity against Candida species. TCZ has been shown to be more active than imidazoles. Objectives: The aim of this research was to assure the potential of proniosomalgelfor the topical delivery of terconazole, and to detect its MIC against Candida albicans comparing it with the reported MIC of terconazole cream 0.8%. Methodology: The coacervation phase separation process was used to develop Terconazole-loaded proniosomal gels. The particle size (PS) and entrapment efficiency percentage of the produced proniosomal gels were assessed and in-vitro drug release. The particle size varies from (17.06–to 48.1 nm), range of EE% is (83.41%–95.66%). F4 (span 60, tween 80 (1:1), and cholesterol) have the highest EE% (95.66%), was tested by Transmission electron microscopy (TEM) and a zeta potential (ZP) test were performed. Results: The outcomes revealed a nanosized spherical vesicleofterconazole. Proniosomal gel MIC was (32µg/ml) lower than the reported MIC of market terconazole cream 0.8% (128µg/ml). Conclusion: Proniosomal gel achieved the desired sustained topical effect.There was no significant change in EE percent, PS, or ZP in physical stability investigation. | ||||
| Keywords | ||||
| Terconazole; Candidiasis; Antimycotic; Proniosomal gel; Stability study | ||||
|
Statistics Article View: 209 PDF Download: 191 |
||||
